SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-134885
Filing Date
2018-04-26
Accepted
2018-04-26 16:26:04
Documents
4
Period of Report
2018-06-13
Effectiveness Date
2018-04-26

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d463334ddef14a.htm DEF 14A 380215
2 GRAPHIC g463334g83b78.jpg GRAPHIC 19362
3 GRAPHIC g463334img001.jpg GRAPHIC 284467
4 GRAPHIC g463334img002.jpg GRAPHIC 185117
  Complete submission text file 0001193125-18-134885.txt   1055194
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 18778941
SIC: 2836 Biological Products, (No Diagnostic Substances)